ZYME vs. BHC, ARVN, MRVI, DCPH, RYTM, AGIO, GERN, VERA, AMPH, and AMRX
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Bausch Health Companies (BHC), Arvinas (ARVN), Maravai LifeSciences (MRVI), Deciphera Pharmaceuticals (DCPH), Rhythm Pharmaceuticals (RYTM), Agios Pharmaceuticals (AGIO), Geron (GERN), Vera Therapeutics (VERA), Amphastar Pharmaceuticals (AMPH), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical preparations" industry.
Bausch Health Companies (NYSE:BHC) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings.
In the previous week, Bausch Health Companies had 6 more articles in the media than Zymeworks. MarketBeat recorded 8 mentions for Bausch Health Companies and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of -0.13 beat Bausch Health Companies' score of -0.44 indicating that Bausch Health Companies is being referred to more favorably in the media.
78.7% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 8.1% of Bausch Health Companies shares are owned by insiders. Comparatively, 1.2% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Bausch Health Companies has a net margin of -5.07% compared to Bausch Health Companies' net margin of -249.63%. Bausch Health Companies' return on equity of -28.37% beat Zymeworks' return on equity.
Bausch Health Companies currently has a consensus price target of $11.33, indicating a potential upside of 72.76%. Zymeworks has a consensus price target of $12.67, indicating a potential upside of 49.37%. Given Zymeworks' higher probable upside, equities analysts clearly believe Bausch Health Companies is more favorable than Zymeworks.
Bausch Health Companies has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.
Bausch Health Companies received 65 more outperform votes than Zymeworks when rated by MarketBeat users. However, 68.59% of users gave Zymeworks an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.
Zymeworks has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Summary
Bausch Health Companies and Zymeworks tied by winning 9 of the 18 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
